Hospital
Providence Health System - Southern California
Providence Health System - Southern California was paid $54.07M by Medicaid between Jan 2018 and Dec 2024, across 304 billing codes. Its largest line is 0450, Emergency room services — 28% of everything it billed.
33Billing provider infoPROVIDENCE HEALTH SYSTEM - SOUTHERN CALIFORNIA
MISSION HILLS, CA 91345
MISSION HILLS, CA 91345
33aNPI1477587632assigned 07/11/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$54.07M
24GClaims1,641,648
24DCodes billed304
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#56 of 410
Median peer was paid$6.90M
This provider vs. median7.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 268,333 | $7.61M | |
| 2019 | 230,264 | $10.79M | |
| 2020 | 164,397 | $4.78M | |
| 2021 | 201,757 | $5.48M | |
| 2022 | 241,742 | $7.84M | |
| 2023 | 277,623 | $9.46M | |
| 2024incomplete | 257,532 | $8.11M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 28% | 218,376 | 197,882 | $15.04M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 6.6% | 28,364 | 24,937 | $3.57M |
| 80053 | Comprehensive metabolic panel | 5.7% | 78,094 | 72,187 | $3.07M |
| 70450 | Computed tomography, head or brain; without contrast material | 5.1% | 16,854 | 16,316 | $2.75M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.2% | 13,053 | 12,678 | $2.24M |
| 99199 | Unlisted special service, procedure or report | 2.9% | 22,560 | 20,137 | $1.56M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.5% | 5,486 | 5,312 | $1.33M |
| Z7502 | 1.9% | 28,627 | 28,237 | $1.04M | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 41,238 | 39,024 | $1.04M |
| 71045 | Radiologic examination, chest; single view | 1.8% | 51,159 | 49,020 | $972K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 87,935 | 81,185 | $951K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 25,589 | 24,053 | $886K |
292 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 22,976 | $612K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.1% | 2,679 | $592K |
| 99285 | Emergency room visit (most serious) | 1.1% | 5,272 | $590K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 6,867 | $536K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 21,289 | $535K |
| 99283 | Emergency room visit (moderate) | <1% | 7,718 | $507K |
| 81001 | <1% | 51,630 | $488K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 25,980 | $486K |
| 99284 | Emergency room visit (serious) | <1% | 7,704 | $395K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,044 | $391K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 15,932 | $382K |
| 83690 | <1% | 39,652 | $368K | |
| 0762 | <1% | 2,495 | $360K | |
| 84484 | <1% | 29,467 | $358K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,987 | $343K |
| 76801 | <1% | 5,209 | $327K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,661 | $321K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 7,752 | $306K |
| 81025 | <1% | 47,813 | $305K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,739 | $302K |
| 0250 | <1% | 35,143 | $300K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 23,470 | $275K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,276 | $252K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 9,162 | $251K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 6,904 | $249K |
| 81003 | <1% | 35,368 | $244K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,365 | $229K |
| 93975 | <1% | 1,459 | $228K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,251 | $228K |
| 76830 | Ultrasound, transvaginal | <1% | 3,492 | $223K |
| 0214 | <1% | 172 | $221K | |
| Z9725 | <1% | 4,947 | $213K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,027 | $210K |
| 93971 | <1% | 2,378 | $205K | |
| 93970 | <1% | 1,455 | $204K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 54,024 | $193K |
| 83880 | <1% | 7,973 | $186K | |
| 70486 | <1% | 1,105 | $185K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,524 | $183K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,067 | $174K |
| 83605 | <1% | 10,954 | $173K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,237 | $171K |
| 87040 | <1% | 13,292 | $171K | |
| 73630 | <1% | 4,818 | $159K | |
| 72100 | <1% | 3,774 | $156K | |
| 73610 | <1% | 4,538 | $155K | |
| 85027 | <1% | 17,623 | $150K | |
| 86901 | <1% | 6,704 | $138K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 16,262 | $137K |
| 73030 | <1% | 3,504 | $135K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 21,423 | $122K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,329 | $119K |
| 59025 | Fetal non-stress test | <1% | 9,789 | $112K |
| J3490 | Unclassified drugs | <1% | 20,856 | $110K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 404 | $108K |
| 73130 | <1% | 3,934 | $104K | |
| 93458 | <1% | 200 | $104K | |
| 85610 | <1% | 13,143 | $96K | |
| 0760 | <1% | 3,524 | $95K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 16,066 | $93K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,091 | $88K |
| 84702 | <1% | 5,961 | $87K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,194 | $86K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 632 | $85K |
| 85730 | <1% | 7,509 | $84K | |
| 84145 | <1% | 5,824 | $83K | |
| 73110 | <1% | 2,342 | $81K | |
| 73562 | <1% | 2,128 | $80K | |
| 71250 | <1% | 888 | $79K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,318 | $79K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,517 | $76K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,064 | $73K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,756 | $70K |
| 90715 | <1% | 1,622 | $69K | |
| 0160 | <1% | 1,193 | $67K | |
| 76870 | <1% | 989 | $67K | |
| 73590 | <1% | 1,529 | $65K | |
| 72040 | <1% | 1,780 | $64K | |
| 73560 | <1% | 3,027 | $63K | |
| 83735 | <1% | 7,744 | $63K | |
| 74018 | <1% | 2,289 | $62K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,986 | $62K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,955 | $62K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,490 | $59K |
| 70496 | <1% | 221 | $57K | |
| 0710 | <1% | 3,983 | $57K | |
| 0206 | <1% | 81 | $56K | |
| 86900 | <1% | 6,684 | $56K | |
| 85379 | <1% | 3,530 | $55K | |
| 0122 | <1% | 41 | $53K | |
| 87077 | <1% | 5,263 | $51K | |
| 0121 | <1% | 29 | $49K | |
| 87186 | <1% | 5,883 | $46K | |
| 96376 | <1% | 4,635 | $46K | |
| 76770 | <1% | 774 | $46K | |
| 99221 | <1% | 2,109 | $46K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 6,078 | $45K |
| 0761 | <1% | 1,371 | $45K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,745 | $43K |
| 87631 | <1% | 898 | $40K | |
| 73140 | <1% | 1,444 | $40K | |
| 73502 | <1% | 1,096 | $40K | |
| 70498 | <1% | 227 | $40K | |
| 86850 | <1% | 2,674 | $36K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,869 | $35K |
| 0682 | <1% | 24 | $35K | |
| 0270 | <1% | 15,137 | $33K | |
| 84703 | <1% | 2,344 | $33K | |
| 73070 | <1% | 1,199 | $31K | |
| 87807 | <1% | 1,037 | $28K | |
| 71101 | <1% | 699 | $28K | |
| 73090 | <1% | 1,046 | $27K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 5,796 | $26K |
| 84439 | <1% | 2,804 | $25K | |
| 72170 | <1% | 1,104 | $25K | |
| 80143 | <1% | 943 | $24K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 591 | $24K |
| 0360 | <1% | 941 | $24K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 221 | $24K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,548 | $24K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 477 | $24K |
| 80179 | <1% | 912 | $23K | |
| G0378 | Hospital observation service, per hour | <1% | 136 | $23K |
| 0370 | <1% | 1,059 | $23K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,198 | $22K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,684 | $22K |
| 92585 | <1% | 523 | $22K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,696 | $21K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,223 | $21K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 89 | $21K |
| Z7500 | <1% | 595 | $20K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,838 | $19K |
| 72072 | <1% | 407 | $19K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,010 | $19K |
| 29125 | <1% | 1,629 | $18K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,229 | $17K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,245 | $17K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,056 | $16K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,656 | $15K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,640 | $15K |
| 82550 | <1% | 1,493 | $15K | |
| 29515 | <1% | 1,497 | $14K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,322 | $14K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,770 | $13K |
| 80306 | <1% | 563 | $13K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 403 | $12K |
| 12001 | <1% | 891 | $11K | |
| 90714 | <1% | 653 | $11K | |
| 93976 | <1% | 94 | $11K | |
| 29130 | <1% | 1,061 | $11K | |
| 87420 | <1% | 369 | $10K | |
| 0272 | <1% | 1,066 | $10K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 45 | $10K |
| 86140 | <1% | 1,804 | $10K | |
| 85652 | <1% | 1,174 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 924 | $9K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 54 | $9K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,353 | $9K |
| 96367 | <1% | 350 | $9K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 25 | $9K |
| 87081 | <1% | 1,062 | $9K | |
| 87400 | <1% | 739 | $9K | |
| 97161 | <1% | 234 | $8K | |
| 93017 | <1% | 187 | $8K | |
| 72131 | <1% | 66 | $8K | |
| 73552 | <1% | 283 | $8K | |
| 87205 | <1% | 1,187 | $8K | |
| 80061 | Lipid panel | <1% | 863 | $8K |
| 29105 | <1% | 537 | $8K | |
| V5008 | Hearing screening | <1% | 987 | $8K |
| 74022 | <1% | 186 | $7K | |
| 86308 | <1% | 799 | $7K | |
| 87070 | <1% | 447 | $7K | |
| 29505 | <1% | 574 | $7K | |
| 73060 | <1% | 245 | $7K | |
| A4217 | Sterile water/saline, 500 ml | <1% | 1,441 | $7K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 39 | $7K |
| J1815 | Injection, insulin, per 5 units | <1% | 809 | $7K |
| Z7610 | <1% | 2,565 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,655 | $6K |
| 12011 | <1% | 282 | $6K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 580 | $6K |
| 82150 | <1% | 567 | $6K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 32 | $6K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 92 | $5K |
| 87210 | <1% | 609 | $5K | |
| 92558 | <1% | 205 | $5K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 527 | $5K |
| 0636 | <1% | 5,586 | $4K | |
| A4649 | Surgical supply; miscellaneous | <1% | 3,070 | $4K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,339 | $4K |
| 73080 | <1% | 147 | $4K | |
| 0301 | <1% | 1,308 | $4K | |
| 0940 | <1% | 188 | $4K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 9,517 | $4K |
| 0324 | <1% | 874 | $4K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 196 | $3K |
| 99152 | <1% | 146 | $3K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 196 | $3K |
| 81002 | <1% | 776 | $3K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 119 | $3K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 577 | $3K |
| 0361 | <1% | 31 | $3K | |
| 84100 | <1% | 683 | $3K | |
| 82805 | <1% | 136 | $2K | |
| 84550 | <1% | 585 | $2K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 220 | $2K |
| 0171 | Inj, epinephrine (belcher) | <1% | 12 | $2K |
| 76818 | <1% | 401 | $2K | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 12 | $2K |
| 71010 | <1% | 268 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 223 | $2K |
| 82077 | <1% | 29 | $1K | |
| 70360 | <1% | 71 | $1K | |
| 12002 | <1% | 76 | $1K | |
| 0300 | <1% | 1,674 | $1K | |
| 0350 | <1% | 1,554 | $1K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 104 | $1K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 93 | $1K |
| 76010 | <1% | 13 | $1K | |
| 93990 | <1% | 15 | $1K | |
| C1769 | Guide wire | <1% | 260 | $1K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 130 | $945.18 |
| 88342 | <1% | 46 | $907.66 | |
| 73620 | <1% | 55 | $905.41 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 126 | $746.80 |
| 10061 | <1% | 73 | $745.60 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 138 | $742.80 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 108 | $707.29 |
| 10060 | <1% | 63 | $629.18 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 101 | $612.29 |
| 97116 | <1% | 190 | $586.14 | |
| 87147 | <1% | 76 | $572.23 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 12 | $568.97 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,708 | $547.54 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 134 | $441.63 |
| 0470 | <1% | 16 | $400.15 | |
| 82330 | <1% | 68 | $339.22 | |
| 82731 | <1% | 15 | $332.18 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 46 | $313.52 |
| 87088 | <1% | 45 | $271.93 | |
| 85018 | <1% | 119 | $267.66 | |
| 73660 | <1% | 12 | $266.51 | |
| 83550 | <1% | 43 | $252.97 | |
| 76857 | <1% | 12 | $230.24 | |
| 83540 | <1% | 43 | $220.15 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 13 | $209.03 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 48 | $191.58 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 428 | $189.79 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 40 | $188.80 |
| 85651 | <1% | 28 | $174.23 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 52 | $173.71 |
| 0258 | <1% | 661 | $164.68 | |
| 36600 | <1% | 29 | $162.42 | |
| 86920 | <1% | 13 | $147.20 | |
| 0410 | <1% | 206 | $142.19 | |
| 82728 | <1% | 14 | $134.23 | |
| 86592 | <1% | 26 | $118.01 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 35 | $115.96 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 17 | $107.41 |
| 0637 | <1% | 641 | $103.83 | |
| 82570 | <1% | 29 | $68.12 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 29 | $48.87 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 13 | $34.64 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 14 | $32.96 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 12 | $26.68 |
| 88304 | <1% | 13 | $21.66 | |
| 0302 | <1% | 588 | $12.07 | |
| 99001 | <1% | 15 | $4.97 | |
| 0305 | <1% | 898 | $4.97 | |
| A9270 | Non-covered item or service | <1% | 391 | $4.51 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 13 | $3.50 |
| 0307 | <1% | 456 | $2.80 | |
| 99070 | <1% | 37 | $0.89 | |
| 0320 | 0% | 93 | $0.00 | |
| 0730 | 0% | 299 | $0.00 | |
| 0480 | 0% | 103 | $0.00 | |
| 0402 | 0% | 150 | $0.00 | |
| 0424 | 0% | 94 | $0.00 | |
| 0921 | 0% | 13 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 28 | $0.00 |
| 15853 | 0% | 40 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 12 | $0.00 |
| A0425 | Ground mileage, per statute mile | 0% | 43 | $0.00 |
| 0278 | 0% | 43 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 28 | $0.00 |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 2,145 | $0.00 |
| 0255 | 0% | 85 | $0.00 | |
| 0306 | 0% | 639 | $0.00 | |
| 0771 | 0% | 29 | $0.00 | |
| 0420 | 0% | 94 | $0.00 | |
| 0310 | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY ENROLLMENTS)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.